The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity to GSK1120212 was profiled for 218 solid tumor cell lines and 81 hematologic malignancy cell lines. For solid tumors, RAF/RAS mutation was a strong predictor of sensitivity. Among RAF/RAS mutant lines, co-occurring PIK3CA/PTEN mutations conferred a cytostatic ...

Diabetes is often complicated by the development of neuropathy, with up to a third of the direct costs of diabetes attributed to neuropathyrelated morbidity (1). The incidence of diabetic neuropathy increases with duration of diabetes, affecting up to 50% of diabetic patients after 25 years of disease (2). To date, the development of neuroprotective and disease-modifying approaches for diabetic...

When there are no compelling biologic or early trial data for a candidate predictive biomarker with regard to its ability to predict the effect of an anticancer treatment at the initiation of definitive phase III trials, it is generally reasonable to include all patients as eligible for randomization but to plan for a prospective subgroup analysis based on the biomarker. We assessed such statis...

Background: Cardiovascular diseases are the leading cause of mortality worldwide. Therefore, it is important to predict the future consequences of the disease in patients who have recovered. Objectives: We sought to determine the relationship between troponin-I level and 6-month clinical consequences (i.e., re-infarction, death, re-angiography and coronary artery bypass grafting) in patients w...

High-risk breast cancer comprises distinct tumor entities such as triple-negative breast cancer (TNBC) which is characterized by lack of estrogen (ER) and progesterone (PR) and the HER2 receptor and breast malignancies which have spread to more than three lymph nodes. For such patients, current (inter)national guidelines recommend anthracycline-based chemotherapy as the standard of care, but no...

Measurement error in self-reported sugars intake may explain the lack of consistency in the epidemiologic evidence on the association between sugars and disease risk. This review describes the development and applications of a biomarker of sugars intake, informs its future use and recommends directions for future research. Recently, 24 h urinary sucrose and fructose were suggested as a predicti...

A delay in diagnosing hollow viscus injury (HVI) causes an increase in mortality and morbidity. HVI remains a challenge to diagnose, and there is no specific diagnostic biomarker for HVI. We evaluated the utility of intestinal fatty acid-binding protein (I-FABP) in diagnosing HVI in blunt trauma patients. Within a 5-year period, 93 consecutive patients with clinically suspected HVI at our traum...

Introduction: RAS status is a predictive biomarker for anti-EGFR response in metastatic colorectal cancer (mCRC). The Idylla technology (IT) fully automated molecular testing system based on real-time PCR and provides rapid results very short preparation time. In this study, we aimed to evaluate the full mutation Moroccan patients with mCRC.

BACKGROUND A predictive biomarker for intake of total sugars was recently developed under controlled conditions. We used this biomarker to assess measurement error (ME) structure in self-reported intake of total sugars in free-living individuals. METHODS The Observing Protein and Energy Nutrition (OPEN) study involved 484 participants aged 40 to 69 years. Diet was assessed using two administr...

saliva is multifunctional; it is a lubricant for speech, aide for food digestion, and protective against microorganisms. it is voluntarily accessible, composed of proteins and electrolytes, and is ideal for the early detection of a wide range of diseases. because of a complex protein mixture, saliva proteomics has the potential to be a novel approach in the search for protein biomarkers. most s...